Division of Colon and Rectal Surgery, Department of Surgery, Taipei-Veterans General Hospital, No 201,Sec 2, Shih-Pai Rd, 11217, Taipei, Taiwan.
Department of Surgery, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.
World J Surg Oncol. 2018 Jul 5;16(1):128. doi: 10.1186/s12957-018-1431-5.
The incidence, site distribution, and mortality rates of patients with colorectal cancer differ according to gender. We investigated gene mutations in colorectal patients and wanted to examine gender-specific differences.
A total of 1505 patients who underwent surgical intervention for colorectal cancer were recruited from March 2000 to January 2010 at Taipei Veterans' General Hospital and investigated for gene mutations in K-ras, N-ras, H-ras, BRAF, loss of 18q, APC, p53, SMAD4, TGF-β, PIK3CA, PTEN, FBXW7, AKT1, and MSI.
There were significant differences between male and female patients in terms of tumor location (p < 0.0001) and pathological stage (p = 0.011). The female patients had significantly more gene mutations in BRAF (6.4 vs. 3.3%, OR 1.985, p = 0.006), TGF-β (4.7 vs. 2.5%, OR 1.887, p = 0.027), and revealed a MSI-high status (14.0 vs. 8.3%, OR 1.800, p = 0.001) than male patients. Male patients had significantly more gene mutations in N-ras (5.1 vs. 2.3%, OR 2.227, p = 0.012); however, the significance was maintained only for mutations in BRAF (OR 2.104, p = 0.038), MSI-high status (OR 2.003 p = 0.001), and N-ras (OR 3.000, p = 0.010) after the groups were divided by tumor site.
Gene mutations in BRAF, MSI-high status, and N-ras differ according to gender among patients with colorectal cancer.
结直肠癌患者的发病率、部位分布和死亡率因性别而异。我们研究了结直肠癌患者的基因突变，并希望检查性别特异性差异。
我们招募了 1505 名 2000 年 3 月至 2010 年 1 月在台北荣民总医院接受结直肠癌手术的患者，对 K-ras、N-ras、H-ras、BRAF、18q 缺失、APC、p53、SMAD4、TGF-β、PIK3CA、PTEN、FBXW7、AKT1 和 MSI 的基因突变进行了研究。
在肿瘤部位（p<0.0001）和病理分期（p=0.011）方面，男性和女性患者存在显著差异。与男性患者相比，女性患者 BRAF（6.4%对 3.3%，OR 1.985，p=0.006）、TGF-β（4.7%对 2.5%，OR 1.887，p=0.027）和 MSI-高状态（14.0%对 8.3%，OR 1.800，p=0.001）的基因突变明显更多。男性患者 N-ras 的基因突变明显更多（5.1%对 2.3%，OR 2.227，p=0.012）；然而，在按肿瘤部位分组后，只有 BRAF 的基因突变（OR 2.104，p=0.038）、MSI-高状态（OR 2.003，p=0.001）和 N-ras（OR 3.000，p=0.010）的意义仍保持不变。
结直肠癌患者的 BRAF 基因突变、MSI-高状态和 N-ras 基因突变存在性别差异。
